Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies (TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS disorders, has announced new stock option grants. The Compensation Committee approved options for 822,000 shares to five new employees on April 1, 2025, under the company's 2023 Inducement Plan.
The options were granted at an exercise price of $1.265, matching the closing price on the grant date. These 10-year options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following 36 months, contingent on continued employment.
Taysha Gene Therapies (TSHA), un'azienda biotech in fase clinica specializzata in terapie geniche basate su AAV per disturbi del sistema nervoso centrale, ha annunciato nuove concessioni di opzioni sulle azioni. Il Comitato per la Compensazione ha approvato opzioni per 822.000 azioni a cinque nuovi dipendenti il 1 aprile 2025, nell'ambito del Piano di Induzione 2023 dell'azienda.
Le opzioni sono state concesse a un prezzo di esercizio di $1.265, corrispondente al prezzo di chiusura alla data di concessione. Queste opzioni di 10 anni matureranno nel corso di quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei successivi 36 mesi, a condizione di un impiego continuato.
Taysha Gene Therapies (TSHA), una empresa biotecnológica en etapa clínica especializada en terapias génicas basadas en AAV para trastornos del sistema nervioso central, ha anunciado nuevas concesiones de opciones sobre acciones. El Comité de Compensación aprobó opciones para 822,000 acciones para cinco nuevos empleados el 1 de abril de 2025, bajo el Plan de Inducción 2023 de la empresa.
Las opciones se otorgaron a un precio de ejercicio de $1.265, que coincide con el precio de cierre en la fecha de concesión. Estas opciones de 10 años se consolidarán a lo largo de cuatro años, con el 25% consolidándose después del primer año y el 75% restante consolidándose mensualmente durante los siguientes 36 meses, condicionado a la continuidad del empleo.
Taysha Gene Therapies (TSHA)는 중추 신경계 질환을 위한 AAV 기반 유전자 치료를 전문으로 하는 임상 단계의 생명공학 회사로, 새로운 주식 옵션 부여를 발표했습니다. 보상 위원회는 2025년 4월 1일에 822,000주의 옵션을 다섯 명의 신규 직원에게 승인했습니다. 이는 회사의 2023 유도 계획에 따른 것입니다.
옵션은 행사 가격 $1.265로 부여되었으며, 이는 부여일의 종가와 일치합니다. 이 10년 옵션은 4년에 걸쳐 발생하며, 첫 해 후 25%가 발생하고 나머지 75%는 다음 36개월 동안 매달 발생합니다. 이는 지속적인 고용에 따라 달라집니다.
Taysha Gene Therapies (TSHA), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies géniques basées sur AAV pour les troubles du système nerveux central, a annoncé de nouvelles attributions d'options sur actions. Le Comité de Rémunération a approuvé des options pour 822 000 actions pour cinq nouveaux employés le 1er avril 2025, dans le cadre du Plan d'Induction 2023 de l'entreprise.
Les options ont été attribuées à un prix d'exercice de 1,265 $, correspondant au prix de clôture à la date d'attribution. Ces options de 10 ans seront acquises sur quatre ans, avec 25 % acquis après la première année et les 75 % restants acquis mensuellement au cours des 36 mois suivants, sous réserve d'un emploi continu.
Taysha Gene Therapies (TSHA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf AAV-basierte Gentherapien für Erkrankungen des zentralen Nervensystems spezialisiert hat, hat neue Aktienoptionsvergaben angekündigt. Der Vergütungsausschuss genehmigte Optionen für 822.000 Aktien für fünf neue Mitarbeiter am 1. April 2025 im Rahmen des Unternehmensplans zur Anwerbung 2023.
Die Optionen wurden zu einem Ausübungspreis von $1.265 gewährt, der dem Schlusskurs am Gewährungstag entspricht. Diese 10-Jahres-Optionen werden über vier Jahre fällig, wobei 25% nach dem ersten Jahr fällig werden und die verbleibenden 75% monatlich über die folgenden 36 Monate fällig werden, abhängig von einer fortgesetzten Beschäftigung.
- New employee hiring indicates company expansion and execution of growth strategy
- Potential shareholder dilution from 822,000 new stock options
DALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2025, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, options to purchase 822,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
How many shares were included in TSHA's April 2025 employee stock option grant?
What is the exercise price for TSHA's April 2025 stock options?
What is the vesting schedule for TSHA's April 2025 employee stock options?
Under which plan were TSHA's April 2025 stock options granted?
